SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE) today reported financial results for the first quarter ended March 31, 2008. The company ended the quarter with approximately $114.9 million in cash, cash equivalents and short-term investments. This figure does not include the $50.0 million payment received from Takeda Pharmaceutical Company Limited in April 2008 pursuant to the collaboration agreement announced on March 31, 2008 for the development and commercialization of GVAX immunotherapy for prostate cancer.
